Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Monotherapy with DCE-US in Metastatic Colorectal Cancer
NCT03264274Phase 2Withdrawn
- Sponsor
- Barts Health NHS Trust
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of aflibercept in colorectal cancer (CRC), sponsored by Barts Health NHS Trust. Planned start Feb 2017; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03264274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264274.